Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CRIS 
Curis Inc (CRIS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/21/2025: CRIS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.33
1 Year Target Price $16.33
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.1% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/21/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 19.75M USD | Price to earnings Ratio - | 1Y Target Price 16.33 |
Price to earnings Ratio - | 1Y Target Price 16.33 | ||
Volume (30-day avg) 5 | Beta 3.86 | 52 Weeks Range 1.02 - 5.38 | Updated Date 10/20/2025 |
52 Weeks Range 1.02 - 5.38 | Updated Date 10/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -300.15% |
Management Effectiveness
Return on Assets (TTM) -59.59% | Return on Equity (TTM) -2951.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12294153 | Price to Sales(TTM) 1.73 |
Enterprise Value 12294153 | Price to Sales(TTM) 1.73 | ||
Enterprise Value to Revenue 1.08 | Enterprise Value to EBITDA 0.56 | Shares Outstanding 12498853 | Shares Floating 9745106 |
Shares Outstanding 12498853 | Shares Floating 9745106 | ||
Percent Insiders 7.23 | Percent Institutions 34.48 |
Upturn AI SWOT
Curis Inc
Company Overview
History and Background
Curis, Inc. is a biotechnology company founded in 2000. Initially focused on developing small molecule drugs, the company has evolved to concentrate on immuno-oncology and precision oncology approaches for cancer treatment. Early milestones included research collaborations with major pharmaceutical companies.
Core Business Areas
- Oncology Drug Development: Curis focuses on developing and commercializing innovative cancer therapeutics. Their pipeline includes drugs targeting cancer pathways.
Leadership and Structure
The leadership team consists of the CEO, CMO, CFO and other key executives. The company has a traditional corporate structure with departments for research, development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- Emavusertib: An oral IRAK4 inhibitor being investigated in lymphoma and other hematologic malignancies. No current market share data available. Competitors include companies developing similar kinase inhibitors.
Market Dynamics
Industry Overview
The oncology therapeutics market is highly competitive and rapidly evolving, driven by advancements in genomics, immunology, and targeted therapies. There is significant unmet need for effective cancer treatments.
Positioning
Curis is a smaller player in the oncology market, focused on a niche area with its IRAK4 inhibitor. Its success depends on the clinical trial results and subsequent commercialization of emavusertib.
Total Addressable Market (TAM)
The global oncology market is estimated to be hundreds of billions of dollars. Curis' TAM is specifically linked to the IRAK4-targeted therapy market, which is a subset of the broader oncology market. Current IRAK4 target market is difficult to assess, with total oncology TAM in the US in 2024 being $150B.
Upturn SWOT Analysis
Strengths
- Novel IRAK4 inhibitor with potential in multiple hematologic malignancies
- Experienced management team with expertise in drug development
- Partnerships with research institutions.
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on the success of a small number of drug candidates
- Historically, Curis has struggled to bring drugs to market successfully
Opportunities
- Potential for breakthrough therapy designation for emavusertib
- Expansion into new indications for IRAK4 inhibition
- Acquisition or partnership with a larger pharmaceutical company.
Threats
- Clinical trial failures
- Competition from other companies developing similar therapies
- Regulatory hurdles and delays
- Patent expiry
Competitors and Market Share
Key Competitors
- MRTX
- ARRY
- VRTX
Competitive Landscape
Curis faces intense competition from larger, well-funded pharmaceutical companies. Its success depends on differentiation of emavusertib and effective execution of clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Curis' growth has been inconsistent, with periods of optimism followed by setbacks. Its dependency on clinical trial results means performance has been variable.
Future Projections: Future growth depends on the success of emavusertib and other pipeline candidates. Analyst estimates vary widely. The company has potential for strong future growth if it receives FDA approval
Recent Initiatives: Recent initiatives include advancing emavusertib through clinical trials and exploring potential partnerships.
Summary
Curis is a small biotechnology company focused on oncology, particularly with its IRAK4 inhibitor, emavusertib. Its success hinges on clinical trial outcomes and securing partnerships due to its limited financial resources. While the company has potential in a large market, its weaknesses and the presence of larger competitors present significant challenges. Investors should closely monitor clinical trial progress and the company's ability to secure funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry publications
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Investment decisions should be based on individual due diligence and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Curis Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2000-08-01 | President, CEO, Secretary, Treasurer & Director Mr. James E. Dentzer | ||
Sector Healthcare | Industry Biotechnology | Full time employees 34 | Website https://www.curis.com |
Full time employees 34 | Website https://www.curis.com | ||
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.